EyePoint Pharmaceuticals, Inc.
EYPT
$11.21
$0.131.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -92.78% | -54.33% | -193.63% | -132.80% | -34.49% |
| Total Depreciation and Amortization | 48.62% | 64.03% | 316.96% | 254.78% | 174.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -20.25% | -49.79% | 96.13% | 55.15% | 85.41% |
| Change in Net Operating Assets | -382.85% | -1.36% | 91.06% | -148.45% | -95.68% |
| Cash from Operations | -210.18% | -70.41% | -55.13% | -156.70% | -135.39% |
| Capital Expenditure | -35.56% | 76.88% | 56.51% | 8.49% | -127.27% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 131.07% | 80.91% | -106.59% | -- | -1,250.51% |
| Cash from Investing | 130.14% | 89.97% | -103.53% | 1,041.63% | -1,291.02% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -56.32% | -87.00% | -30.40% | 11.76% | 12,400.00% |
| Repurchase of Common Stock | 75.64% | 72.04% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -226.97% | -913.89% | 100.00% | 83.85% |
| Cash from Financing | -27.66% | -926.96% | -30.57% | 14.78% | 100.90% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 92.22% | -41.91% | -86.59% | -66.70% | -632.76% |